Colgate-Palmolive heads into its July 31 earnings date with options traders at their most bullish in a year and the stock building momentum off a multi-month recovery.
The clearest signal this week is in options. The put/call ratio has dropped to 0.67 — nearly 1.7 standard deviations below its 20-day average of 0.82, and right at the 52-week low of 0.67. That's a meaningful tilt toward calls over puts. The shift is sharp: through most of June the PCR ran between 0.82 and 0.94, reflecting a more balanced or cautious stance. Something changed in the last two weeks of June, and call demand has climbed steadily since. With earnings three weeks away, that move reads as positioning rather than noise.
Price performance supports the tone. The stock gained 3.7% on the week and 7.3% over the past month, closing at $95.03. That recovery brings it almost exactly to where Wells Fargo raised its target on July 8 — analyst Chris Carey lifted the Equal-Weight price objective from $92 to $95, a signal the firm sees fair value near current levels rather than meaningful upside. Bernstein initiated coverage in June with a Market Perform and $96 target. The holdouts are more constructive: JP Morgan and UBS both carry Buy-equivalent ratings with targets of $96 and $100 respectively, and RBC has an Outperform with a $102 objective. The Street's center of gravity is a "hold" consensus, but the bull-camp targets cluster just above the current price — suggesting limited near-term re-rating potential even for optimists. The forward PE has drifted up around 23x over the past month, and the EV/EBITDA near 15.6x reflects a stock that is being valued on staples stability rather than growth.
Short interest is not a meaningful part of this week's story. At 2.4% of the free float, it has drifted lower by about 0.4% over the past week and is down roughly 0.7% over the past month. The lending market confirms there is no pressure: availability is effectively unlimited — the borrow pool dwarfs the short interest by orders of magnitude — and the cost to borrow has fallen sharply this week to just 0.30%, down from 0.49% earlier in the month. There is no squeeze dynamic here, no sign of forced covering, and no incremental short positioning building ahead of earnings. The short score of 34.7 has barely moved in two weeks.
The institutional ownership picture is stable and index-heavy. BlackRock reported a position of 72.6 million shares — 9.1% of the company — as of June 30, and added roughly 2.2 million shares in the period. T. Rowe Price held 33.8 million shares as of May with a net add of 2.6 million, while State Street and Geode made smaller additions. The ownership base is broadly passive and long-only, consistent with a dividend-yield stalwart. On that note, the dividend score ranks in the 97th percentile of the ORTEX universe — a standout even among consumer staples names. The insider picture is less interesting: the 90-day net is technically positive at around 34,000 shares, but that reflects award grants offset by routine sales. COO Shane Grant sold $2.1 million of stock at $90.66 in mid-June, which is the most notable single transaction and carries low significance.
Factor scores flag one genuine tension. The 12-month forward EPS growth rank is strong at the 83rd percentile — the Street is still lifting estimates, and the bull case centres on Colgate's 70% international revenue base and pricing power. But EPS momentum over 30 and 90 days both sit in the low-to-mid 30s, and the EPS surprise rank is also around the 34th percentile. That combination — improving long-run forecasts but weak near-term delivery — matches the bear case, which points to margin compression from raw material costs and tariffs, and volume declines of 0.3–0.9% through the first half of 2025. The Hill's pet nutrition business has also been a drag, with measured-channel declines of nearly 3% in recent quarters. Peers ran broadly in line this week: PG added 2.9%, KMB 4.4%, and CHD 1.1%, so the week's gain for Colgate reflects sector tailwind as much as stock-specific momentum.
The July 31 print is the next hard catalyst. Recent earnings history shows a muted immediate reaction — the May 2026 result produced less than a 1% one-day move — but the five-day drift afterwards has been positive. What to watch is whether volume trends have stabilised into Q2 and whether Hill's is recovering, as those two items will determine how much of the PCR shift reflects genuine fundamental conviction versus pre-earnings call buying that unwinds quickly on the day.
See the live data behind this article on ORTEX.
Open CL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
